生物活性：Minodronic acid-d4 is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].
IC50 & Target：P2X2 Receptor
P2X3 Receptor
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Minodronic acid-d4 相关抗体:
ERK1/2 Antibody
E-Cadherin Antibody (YA470)
Fatty Acid Synthase Antibody (YA766)
DYKDDDDK Tag (FLAG) Antibody
GAPDH Antibody
GFP Antibody
p53 Antibody (YA250)
RUNX2 Antibody
Ferritin Heavy Chain Antibody
COX2 Antibody
Ctip2 Antibody
Cyclin D1 Antibody (YA485)
Cytochrome C Antibody
c-Myc Antibody
Cyclin E1 Antibody
AIF Antibody (YA636)
ALIX Antibody
CNPase Antibody
Cortactin Antibody
COX IV Antibody
COX2/Cyclooxygenase 2 Antibody
Cyclin A2 Antibody
Cyclin B1 Antibody (YA486)
DR5 Antibody
Drosha Antibody
E-Cadherin Antibody (YA778)
EEA1 Antibody
EpCAM Antibody (YA772)
Fatty Acid Synthase Antibody
FIP200 Antibody
分子量：326.17
Formula：C9H8D4N2O7P2
CAS 号：1807367-80-1
非标记 CAS：180064-38-4
中文名称：米诺磷酸-d4
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (538 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Sato K, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006 Nov 20;95(10):1354-61.
 [Content Brief]
[3]. Tanaka M, et al. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors. J Bone Miner Metab. 2018 Jan;36(1):54-63.
 [Content Brief]